ProteinQure Inc.
TORONTO, ON / ACCESSWIRE / March 25, 2024 / ProteinQure, the leading startup in the computational design of peptide drugs, announces a significant breakthrough in the fight against triple-negative breast cancer (TNBC). The novel Peptide Drug Conjugate (PDC) designed by ProteinQure demonstrated exceptional efficacy in a comprehensive suite of Patient-Derived Xenograft (PDX) models. The experiments were conducted in the lab of Dr. David Cescon at the Princess Margaret Cancer Centre/University Health Network, one of the world's top five cancer research centres.
Developed through ProteinQure's cutting-edge computational platform, the innovative SORT1 targeting PDC is a novel peptide attached to a highly potent chemotherapeutic agent. The drug candidate was tested across a broad range of breast cancer models. The results demonstrated remarkable antitumor efficacy, including cancers resistant to standard chemotherapies and antibody-drug conjugates.
"Working with the David Cescon Lab at UHN has been instrumental in validating our novel PDC's efficacy against one of the most challenging forms of breast cancer. Based on these results, we are moving our lead program forward into IND-Enabling studies and our first clinical trial," said Lucas Siow, CEO of ProteinQure. "These findings not only highlight the power of our computational drug design platform but also represent significant validation in our quest to develop tissue-specific peptides for targeted drug delivery."
ProteinQure's collaborators will present the data at the upcoming American Association for Cancer Research (AACR) conference in San Diego. The AACR conference, renowned for showcasing the latest innovations in cancer research, provides the perfect stage to share these findings with the global cancer research community.
"We are excited to present this data at AACR and help develop new therapeutic options for breast cancer, especially with promising Canadian startups," stated Dr. David Cescon, head of the lab at UHN. "The success of this unique PDC in diverse PDX models is a testament to the potential of combining advanced computational techniques, precision oncology, and our labs' robust preclinical platform".
Funding for parts of this work included contributions from IRAP-Canada and the INOVAIT program based out of Sunnybrook Hospital.
Poster Presentation Details:
Title: In-vivo efficacy of a novel peptide-conjugated drug in patient-derived xenograft models of breast cancer
Session Title: New Targets
Date and Time: Tuesday, April 9, at 1:30 p.m. PT/4:30 p.m. ET
Abstract Number: 5911
Speaker: Mitchell Elliott, UHN Princess Margaret Cancer Centre
About ProteinQure
ProteinQure is a pioneering startup specializing in the computational design of peptide drugs utilizing state-of-the-art artificial intelligence and molecular simulation technologies. With a focus on precision medicine, ProteinQure is dedicated to transforming the landscape of drug development and ushering in a new era of targeted effective treatments.
About the David Cescon Lab at UHN
The David Cescon Lab at the University Health Network is a leader in breast cancer research, focusing on the mechanisms of cancer progression and resistance to therapy. Through cutting-edge pre-clinical and clinical research and collaborations, the lab develops novel therapeutic strategies aimed at improving outcomes for cancer patients worldwide.
For further information, please contact:
Lucas Siow - CEO of ProteinQure - press@proteinqure.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
SOURCE: ProteinQure Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Announces it has Developed Patented AI Rating Technology Launching Globally with Fintech.TV in Pilot Season14.1.2026 15:15:00 CET | Press release
Introducing AI Content Detection, Real-Time Bias Meter and Breakthrough Interactive Polling Powered by ADIO® PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 14, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today announced a transformative integration of its patented content detection, identification, and rating system (US Patent Publication 2019/0082224 A1) with Fintech.TV, the premier on-demand platform for fintech and AI news. This collaboration leverages Datavault AI's proprietary innovations to enhance viewer engagement and promote fair, balanced media through a revolutionary high performance computation and real-time bias meter and interactive polling utility that is activated via Datavault AI's patented Inaudible Tone® technology known as ADIO. Vince Molinari, CEO of Fintech.tv stated, "Fintech TV is known for exploring cutting-edge technology at the intersection of finance,
Skymantics Announces Strategic Investment and Technology Partnership with Geo Orchestration AI to Advance Generative Risk Analytics14.1.2026 13:30:00 CET | Press release
ZARAGOZA, ES / ACCESS Newswire / January 14, 2026 / Skymantics, a leading provider of AI-driven data analytics solutions, is announcing a strategic partnership with Geo Orchestration AI, a generative AI orchestration engine provider for the healthcare analytics sector. The partnership includes an equity investment by Skymantics' leadership and the appointment of Antonio Correas, Skymantics Co-founder and Chief Growth Officer, to Geo Orchestration AI's Board of Directors. This collaboration marks a significant convergence of technologies, combining Skymantics' DataGenesis synthetic data platform with Geo Orchestration AI's generative orchestration engine, Anna. Building a Developer Ecosystem The partnership was showcased at the American Geophysical Union (AGU) Annual Meeting 2025 in New Orleans. During the event, Skymantics demonstrated local- and national-scale heat and air quality risk analytics solutions built directly upon the Anna platform. This demonstration validates Anna's capab
GA-ASI and USN Test Expanded Sonobuoy Dispensing System For MQ-9B SeaGuardian(R)13.1.2026 19:00:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 13, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and the U.S. Navy continue to expand the Anti-Submarine Warfare (ASW) capability of the MQ-9B SeaGuardian® Unmanned Aircraft System (UAS). Flight test was performed on December 17 and featured Sonobuoy Dispensing System (SDS) pods, more than previously tested, doubling the number of sonobuoys available. "Expanding sonobuoy capacity, including Multi-static Active Coherent (MAC) technology for SeaGuardian, has been an integral part of our advanced ASW strategy to broaden and enhance search areas," said GA-ASI President David R. Alexander. "The wider maritime coverage our MQ-9B's ASW capability provides is extremely valuable to our customers." Sonobuoys are naval sensors that drop from an aircraft into the ocean and help detect submarines. The SeaGuardian deployed AN/SSQ-36 Bathythermal, AN/SSQ-53G Directional Frequency Analysis and Recording (DIFAR) (passive), and AN/SSQ-62F D
Hirth Engines and ePropelled Announce Strategic Collaboration to Advance High-Efficiency Propulsion Systems13.1.2026 15:00:00 CET | Press release
Unifying Strengths to Address a Growing Market COVENTRY, UK / ACCESS Newswire / January 13, 2026 / Hirth Engines, a globally recognized leader in two-stroke engine technology, and ePropelled, an innovator in high-efficiency intelligent electric propulsion and power generation systems , today announced a strategic collaboration aimed at delivering the next generation of hybrid propulsion solutions for the UAV, aerospace, defense, and specialized mobility markets. Driven by increasing demand for reliable, lightweight, and energy-efficient propulsion systems, the partnership brings together Hirth's decades-long expertise in advanced combustion engines with ePropelled's pioneering electric propulsion and power management technologies. Together, the companies will develop integrated hybrid systems designed to offer unmatched performance, extended mission endurance, and greater operational flexibility. Unifying Strengths to Address a Growing Market Under this collaboration, Hirth Engines wil
Polaris Renewable Energy Announces Q4 and Annual 2025 Investor Call Details13.1.2026 15:00:00 CET | Press release
TORONTO, ONTARIO / ACCESS Newswire / January 13, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q4 and annual 2025 Earnings Results on Thursday, February 19th, 2026, at 10:00 am EST. To listen to the call, please dial Toll Free 1 888-506-0062 or International Toll-Free Number 973-528-0011 entry code 743835. or URL: https://www.webcaster4.com/Webcast/Page/2773/51835 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 51835 International (toll-free): 1 919-882-2331, Passcode: 51835 Encore Replay Expiration Date: March 05, 2026 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom